5 Best Shipping Stocks To Invest In 2014

Some smart vulture investors have piled into dry bulk in recent months��nd we already have a horse in this race, notes Igor Greenwald, editor of MLP Profits.

Wilbur Ross became famous for buying up bankrupt US steel mills on the cheap more than a decade ago, and then selling them years later, as demand recovered.

Two months ago, he dipped his toe into another tide of woe by investing in a new shipping venture, Nautical Bulk Holdings, which has raised more than $100 million, and ordered eight ultramax dry bulk behemoths at $24.5 million a pop, to meet rising demand as early as 2015.

Last month, Oaktree Capital (OAK), managed by another distressed investing icon, Howard Marks, disclosed a huge 21.9% stake in Star Bulk Carriers (SBLK).

Why are these financial sharpshooters taking aim at a sector thoroughly beaten down by years of oversupply? Presumably, they've spotted a turning point on the horizon.

International shipping rates, as represented by the Baltic Dry index (BDIY:IND), remain down more than 60% from rates seen as recently as 2010, and before that, as early as 2003.

5 Best Mid Cap Stocks To Own Right Now: Guided Therapeutics Inc (GTHP)

Guided Therapeutics, Inc., incorporated on October 27, 1992, is a medical technology company focused on developing medical devices. The Company�� primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. Its technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix.

The Company's product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions. The product is expected to incorporate a single-use, disposable calibration and alignment component.

The Company competes with Qiagen, MediSpectra, Inc., Merck & Co., Inc., and GlaxoSmithKline PLC.

Advisors' Opinion:

• [By CRWE]

  Last Friday, GTHP had shed (-2.16%) down -0.015 at $.679 with 39,538 shares in play at the close (ref. google finance August 23, 2013 ��Close).

  Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.

  Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.

• [By CRWE]

  Today, GTHP remains (0.00%) +0.000 at $.710 with 44,700 shares in play thus far (ref. google finance Delayed: 11:42AM EDT August 21, 2013).

  Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.

  Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.

5 Best Shipping Stocks To Invest In 2014: Controladora Vuela Compania de Aviacion SAB de CV (VLRS)

Controladora Vuela Compania de Aviacion SAB de CV (Volaris Aviation Holding Company) is a Mexico-based company principally engaged in the airline passenger transportation industry. The Company is a law-cost carrier airline. Controladora Vuela Compania de Aviacion SAB de CV offers direct, point-to-point flights. The Company serves through secondary, lower cost airports and provides a single class of service. The Company utilizes such aircraft as the Airbus A319 and A320 families, among others. The Company has such subsidiaries as Comercializadora Volaris SA de CV, Servicios Corporativos Volaris SA de CV, Concesionaria Vuela Compania de Aviacion SAPI de CV, Deutsche Bank Mexico SA Trust 1484, among others. Advisors' Opinion:

• [By John Udovich]

  When most American investors think of discount airline stocks, they probably think of relatively large capped Southwest Airlines Co (NYSE: LUV)�or sort of small cap�JetBlue Airways Corporation (NASDAQ: JBLU) rather than�small cap Controladora Vuela Co Avcn SA CV (NYSE: VLRS) which owns Volaris���a discount airline serving the�Mexican market. However, any investor who has read Benjamin Graham�� Intelligent Investor might want to remember his sage advice about avoiding airline stocks���mainly because airlines were such a new and unproven sector that had yet to make money. But could Controladora Vuela Co Avcn SA CV actually be an airline stock worth owning?

5 Best Shipping Stocks To Invest In 2014: Ausdrill Ltd (ASL)

Ausdrill Limited is a mining and energy services company providing exploration, mine development, surfacing and underground mining, manufacturing, energy and infrastructure services globally. The Company operates in five segments: Mining Services Australia, which includes the provision of mining services, including drilling and blasting, in-pit grade control, exploration drilling, earthmoving, waterwell drilling, energy drilling, equipment hire, equipment parts and sales and mineral analysis in Australia; Contract Mining Services Africa, which includes the provision of mining services, including drilling and blasting, in pit grade control, exploration drilling and earthmoving in Africa; Manufacturing, which includes manufacture of drilling rods and consumables, drill rigs and dump truck tray bodies; Supply and Logistics, which includes the provision of mining supplies and logistics services and Other, which includes its central functions like treasury, financing and administration. Advisors' Opinion:

• [By Adam Haigh]

  Toyota Motor Corp. (7203), the world�� biggest carmaker, lost 1.3 percent in Tokyo after its net-income forecast fell short of analyst estimates. Ausdrill Ltd. (ASL) slumped 29 percent in Sydney after the drilling contractor said its expects a lower profit. GungHo Online Entertainment Inc. gained 2.5 percent as Japan Exchange Group Inc. and Nikkei Inc. said the Internet-game maker will be included in their new index.

5 Best Shipping Stocks To Invest In 2014: Ironwood Pharmaceuticals Inc.(IRWD)

Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on the research and development of early stage product candidates and preclinical research in various therapeutic areas, including gastrointestinal disease, pain and inflammation, respiratory disease, and cardiovascular disease. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; and a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. It serves patients, payors, and healthcare providers. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Keith Speights]

  Flood of expenses
  Ironwood Pharmaceuticals (NASDAQ: IRWD  ) shares fell 12% this week, after the company reported first-quarter results. A big part of the drugmaker's problems stemmed from soaring sales and administrative costs.

• [By gurujx]

  Ironwood Pharmaceuticals, Inc. (IRWD) Reached the 3-year Low of $10.02

  The prices of Ironwood Pharmaceuticals, Inc. (IRWD) shares have declined to close to the 3-year low of $10.02, which is 51.0% off the 3-year high of $19.67.

• [By Ben Levisohn]

  And it’s not just Gilead that Meacham is feeling good about. He’s also optimistic about Biogen Idec (BIIB), Ironwood Pharmaceuticals (IRWD) and Alexion Pharmaceiticals (ALXN):